Regional differences in gallbladder cancer pathogenesis: Insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression

Annals of Surgical Oncology

Volumn 20, Issue 5, 2013, Pages 1470-1481

  Butte, Jean M ^a,c   Torres, Javiera ^a,d   Veras, Emanuela F ^a   Matsuo, Kenichi ^a,b   Gönen, Mithat ^a   D'Angelica, Michael I ^a   Waugh, Enrique ^c   Meneses, Manuel ^c   Inayama, Yoshiyaki ^b   Fong, Yuman ^a   Dematteo, Ronald P ^a   De La Fuente, Hernan ^c   Endo, Itaru ^b   Klimstra, David S ^a   Jarnagin, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c Instituto Oncológico Fundación Arturo López Pérez   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC PROTEIN; CD1 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHOLECYSTECTOMY; CHOLELITHIASIS; DISEASE SPECIFIC SURVIVAL; FEMALE; GALLBLADDER CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PANCREATICODUODENECTOMY; PATHOGENESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; CHILE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-MDM2; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84880052751     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2761-0     Document Type: Article

References (41)

1. Andia ME, Hsing AW, Andreotti G, Ferreccio C. Geographic variation of gallbladder cancer mortality and risk factors in Chile: a population-based ecologic study. Int J Cancer. 2008;123(6):1411-6.
2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for gallbladder cancer across the world. HPB. 2008;10(5):327-31.
3. Kumar JR, Tewari M, Rai A, Sinha R, Mohapatra SC, Shukla HS. An objective assessment of demography of gallbladder cancer. J Surg Oncol. 2006;93(8):610-4.
4. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-64.
5. Dutta U, Nagi B, Garg PK, Sinha SK, Singh K, Tandon RK. Patients with gallstones develop gallbladder cancer at an earlier age. Eur J Cancer Prev. 2005;14(4):381-5.
6. Elnemr A, Ohta T, Kayahara M, et al. Anomalous pancreaticobiliary ductal junction without bile duct dilatation in gallbladder cancer. Hepatogastroenterology. 2001;48(38):382-6.
7. Kayahara M, Nagakawa T. Recent trends of gallbladder cancer in Japan: an analysis of 4,770 patients. Cancer. 2007;110(3):572-80.
8. Tewari M, Kumar V, Mishra RR, Kumar M, Shukla HS. Is there a role for cholecystectomy in gallbladder carcinoma discovered to be unresectable for cure at laparotomy? World J Surg. 2008;32(12):2683-7.
9. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999;30(1):21-5.
10. Moreno M, Pimentel F, Gazdar AF, Wistuba, II, Miquel JF. TP53 abnormalities are frequent and early events in the sequential pathogenesis of gallbladder carcinoma. Ann Hepatol. 2005;4(3):192-9.
11. Pai RK, Mojtahed K. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol. 2011;19(2):133-40.
12. Butte JM, Matsuo K, Gonen M, et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg. 2011;212(1):50-61.
13. Nakayama K, Konno M, Kanzaki A, et al. Allelotype analysis of gallbladder carcinoma associated with anomalous junction of pancreaticobiliary duct. Cancer Lett. 2001;166(2):135-41.
14. Hanada K, Tsuchida A, Iwao T, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol. 1999;94(6):1638-42.
15. Hanada K, Tsuchida A, Kajiyama G. Cellular kinetics and gene mutations in gallbladder mucosa with an anomalous junction of pancreaticobiliary duct. J Hepatobiliary Pancreat Surg. 1999;6(3):223-8.
16. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996;27(4):360-5.
17. Yokoyama N, Hitomi J, Watanabe H, et al. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev. 1998;7(4):297-301.
18. Hanada K, Itoh M, Fujii K, et al. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer. 1997;33(7):1136-40.
19. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55(2):218-29.
20. Harino Y, Imura S, Kanemura H, et al. Role of tumor angiogenesis in gallbladder carcinoma: with special reference to thymidine phosphorylase. Int J Clin Oncol. 2008;13(5):452-7.
21. Jarnagin WR, Klimstra DS, Hezel M, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol. 2006;24(7):1152-60.
22. Deshpande V, Nduaguba A, Zimmerman SM, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60.
23. Butte JM, Gonen M, Allen PJ, et al. The role of laparoscopic staging in patients with incidental gallbladder cancer. HPB. 2011;13(7):463-72.
24. D'Angelica M, Dalal KM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806-16.
25. AJCC Cancer Staging Handbook. 7 ed. Chicago: American Joint Committee on Cancer; 2010.
26. Sakr RA, Barbashina V, Morrogh M, et al. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol. 2010;18(4):371-4.
27. Della Torre G, Pasquini G, Pilotti S, et al. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol. 2000;9(1):41-6.
28. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 1999;35(3):230-40.
29. Ito Y, Takeda T, Sasaki Y, et al. Bcl-2 expression in cholangiocellular carcinoma is inversely correlated with biologically aggressive phenotypes. Oncology. 2000;59(1):63-7.
30. Ito Y, Takeda T, Sasaki Y, et al. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology. 2001;60(3):242-51.
31. Tenjo T, Toyoda M, Okuda J, et al. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology. 2000;58(1):45-51.
32. Wiksten JP, Lundin J, Nordling S, Kokkola A, von Boguslawski K, Haglund C. The prognostic value of p27 in gastric cancer. Oncology. 2002;63(2):180-4.
33. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591-602.
34. Lemrow SM, Perdue DG, Stewart SL, et al. Gallbladder cancer incidence among American Indians and Alaska Natives, US, 1999-2004. Cancer. 2008;113(5 Suppl):1266-73.
35. Mori K, Nagakawa T, Ohta T, et al. Association between gallbladder cancer and anomalous union of the pancreaticobiliary ductal system. Hepatogastroenterology. 1993;40(1):56-60.
36. Schafer KA. The cell cycle: a review. Vet Pathol. 1998;35(6):461-78.
37. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003;36(3):131-49.
38. da Rocha AO, Coutinho LM, Schall JG. The prognostic value of angiogenesis by Chalkley counting in gallbladder carcinoma. Hepatogastroenterology. 2009;56(89):34-8.
39. Conde E, Angulo B, Tang M, et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res. 2006;12(3 Pt 1):710-7.
40. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene. 2008;27(41):5443-53.
41. Baba Y, Nosho K, Shima K, et al. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011;117(7):1399-408.